TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated at Canaccord Genuity Group

Research analysts at Canaccord Genuity Group began coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) in a research note issued on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 67.60% […]

Related Keywords

, Trisalus Life Sciences Company Profile , Canaccord Genuity Group , Nasdaq , Tyche Wealth Partners , Trisalus Life Sciences Stock Down , Trisalus Life Sciences Inc , Trisalus Life Sciences , News Ratings For Trisalus Life Sciences Daily , Get Free Report , Marketbeat Ratings , Genuity Group , Salus Life Sciences Stock Down , Salus Life Sciences , Wealth Partners , Free Report , Pressure Enabled Drug Delivery , Pancreatic Retrograde Venous Infusion , Trisalus Life Sciences Daily ,